

## Clinical trials information

### PHAEDRA

This trial is **fully enrolled**. This means that all of the available places on the trial have been filled. You cannot enrol in this trial.

#### About this trial

PHAEDRA is an ongoing study following a group of people ('[cohort](#)In epidemiology, a group of individuals with some characteristics in common. A cohort study is a special kind of clinical trial which looks at a treatment or treatment strategy in a cohort of people.') who were [enrolled](#)The act of signing up participants into a study. Generally this process involves evaluating a participant with respect to the eligibility criteria of the study and going through the informed consent process. in the very early period following seroconversion ('primary HIV infection'). The study aim is to explore and characterise some of the immune system responses to HIV in the period following infection, to look at the effects of treatment and to identify any particular factors that may influence the progression of HIV disease. The study will also monitor the transmission of drug-[resistant](#)HIV which has mutated and is less susceptible to the effects of one or more anti-HIV drugs is said to be resistant. HIV.

There is no particular treatment regimen associated with this study. People are free to make their own treatment decisions within this study. People in the study are followed over time, and undergo routine annual collection of medical information including [viral load](#)A measurement of the quantity of HIV RNA in the blood. Viral load blood test results are expressed as the number of copies (of HIV) per milliliter of blood plasma., CD4 count, and other information, such as any illnesses experienced.

#### Background information

Many of the PHAEDRA cohort have rolled over into a separate international primary infection natural history study called CORE01.

##### Official title:

A prospective cohort of individuals with primary HIV infection to determine immunological, virological and therapeutic factors related to disease progression

##### What is this trial studying?

other

##### Start date:

September 2002 (This may be the proposed or expected start date for trials which have not yet started.)

##### Links to further information:

- <http://clinicaltrials.gov/ct2/show/NCT00103961?term=PHAEDRA&rank=1>
- [http://clinicaltrials.gov/ct2/show/NCT00086372?term=CORE01&rank=1&show\\_locs=Y#locn](http://clinicaltrials.gov/ct2/show/NCT00086372?term=CORE01&rank=1&show_locs=Y#locn)

#### Who can enrol in this trial?

You *may* be eligible to participate in this trial if you meet the following criteria:

## **PHAEDRA**

From the NAPWA website at <http://www.napwa.org.au/trials/phaedra>

---

At least 18 years old  
Recently been infected with HIV, or undergoing seroconversion

This is a summary of key inclusion and exclusion criteria for this trial. There may be other criteria which may exclude some people from participation in this trial. Some laboratory tests may also be required. Consult your doctor, or view the trial protocol or informed consent documentation to see the full range of exclusion and inclusion criteria.

### **Disclaimer**

While NAPWA has taken every care to compile the information on this page and to keep it up-to-date, we cannot guarantee its correctness and completeness.

Before making the decision to participate in any clinical research, visit the NAPWA website for background information on participating in clinical research.

Contact NAPWA if you have any questions or comments about this trial.